Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects

Angioedema

“…Patients should be warned to avoid these drugs as a class. Intradermal injection of cysteinyl leukotrienes causes increased inflammatory responses in patients with chronic urticaria 18 and leukotriene antagonists or lipoxygenase inhibitors might be assumed on theoretic grounds to be helpful in patients with NSAID-induced angioedema. 19 Use of leukotriene antagonists to prevent exacerbations as a result of NSAIDS has been advocated, but recent work sheds doubt on their efficacy.…”

Leukotriene E4: Perspective on the forgotten mediator

“…LTE 4 is therefore as potent as LTC 4 and LTD 4 in increasing vascular permeability and vasodilatation. 35 The capacity of LTE 4 uniquely to recruit eosinophils and its potency to elicit vasoactive cutaneous responses relative to other CysLTs cannot be explained by the pharmacology of the established receptors for CysLTs and strongly points to the existence of a novel LTE 4 -specific receptor or receptors.…”

Montelukast in allergic diseases beyond asthma

“…In fact, intradermal injection of LTs has been shown to induce a weal-flare reaction, providing additional evidence that these mediators may participate in the formation of urticaria. 58 H 1 -receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, CU often is difficult to treat and may not be controlled by antihistamines alone.…”